Consensus Exact Sciences Corporation

Equities

EXAS

US30063P1057

Real-time Estimate Cboe BZX 03:18:19 2024-03-28 pm EDT 5-day change 1st Jan Change
69.78 USD +4.34% Intraday chart for Exact Sciences Corporation +13.31% -5.04%

Evolution of the average Target Price on Exact Sciences Corporation

Price target over the last 5 years

History of analyst recommendation changes

d16c5be560be6c1b8400c6e2617.2vvVfRzwZpRNkXi97XDiczbydvbWmfl3Qn-uWXM5MtM.nKOeKEmFAaUI5wnapT2nAwC6NL-P65YxLD7DGipMZpKgzp0PQ6MW2Tz2KQ~c6b3d194225d89b0d93a0b01451cb241
Benchmark Upgrades Exact Sciences to Buy From Hold, Sets Price Target at $91 MT
Goldman Sachs Adjusts Price Target on Exact Sciences to $90 From $100, Keeps Buy Rating MT
BofA Securities Cuts Price Target on Exact Sciences to $88 From $110, Maintains Buy Rating MT
Piper Sandler Upgrades Exact Sciences to Overweight From Neutral, Price Target is $90 MT
Bernstein Starts Exact Sciences With Outperform Rating MT
Baird Adjusts Price Target on Exact Sciences to $121 From $99, Maintains Outperform Rating MT
Benchmark Downgrades Exact Sciences to Hold From Buy MT
Credit Suisse Adjusts Exact Sciences' Price Target to $90 From $75, Keeps Neutral Rating MT
Goldman Sachs Adjusts Price Target on Exact Sciences to $110 From $85, Maintains Buy Rating MT
UBS Raises Exact Sciences' Price Target to $99 From $73, Maintains Neutral Rating MT
Canaccord Genuity Raises Price Target on Exact Sciences to $115 From $92, Maintains Buy Rating MT
ANALYST RECOMMENDATIONS : BAE Systems, Berkeley, Burberry, Reinsurance Group, Tesla... Our Logo
Citigroup Adjusts Price Target on Exact Sciences to $130 From $100, Keeps Buy Rating MT
Exact Sciences says its new colon cancer test shows 30% lower false positive rate RE
Jefferies Raises Exact Sciences' Price Target to $100 From $82, Maintains Buy Rating MT
Citigroup Adjusts Price Target on Exact Sciences to $100 From $90, Maintains Buy Rating MT
Baird Adjusts Price Target on Exact Sciences to $99 From $92, Maintains Outperform Rating MT
BofA Adjusts Price Target on Exact Sciences to $88 From $80, Keeps Buy Rating MT
Credit Suisse Raises Exact Sciences' PT to $75 From $70, Notes Broad-based Momentum, Guide Upgrade; Keeps Neutral Rating MT
Craig Hallum Upgrades Exact Sciences to Buy From Hold, Raises Price Target to $85 From $55 MT
UBS Initiates Coverage on Exact Sciences With Neutral Rating, $73 Price Target MT
Benchmark Adjusts Exact Sciences' Price Target to $78 From $54, Keeps Buy Rating MT
Citigroup Upgrades Exact Sciences to Buy From Neutral, Adjusts Price Target to $90 From $70 MT
Piper Sandler Adjusts Exact Sciences' Price Target to $70 From $50, Keeps Neutral Rating MT
Cowen Raises Price Target on Exact Sciences to $76 From $56, Maintains Outperform Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
66.88 USD
Average target price
88.49 USD
Spread / Average Target
+32.31%
High Price Target
115 USD
Spread / Highest target
+71.95%
Low Price Target
66 USD
Spread / Lowest Target
-1.32%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Exact Sciences Corporation

Benchmark Company
Goldman Sachs
BofA Securities
Piper Sandler
Bernstein
Baird
Credit Suisse
UBS
Canaccord Genuity
Citigroup
Jefferies & Co.
Craig-Hallum
Cowen
Morningstar
BTIG
Raymond James
SVB Securities LLC
Evercore ISI
SVB Leerink
Wells Fargo Securities
Oppenheimer
Truist Securities
Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings